Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season.
J Infect Dis. 2009 Jan 15; 199(2):159-67.JI

Abstract

BACKGROUND

We estimated the effectiveness of inactivated influenza vaccines for the prevention of laboratory-confirmed, medically attended influenza during 3 seasons with variable antigenic match between vaccine and patient strains.

METHODS

Patients were enrolled during or after a clinical encounter for acute respiratory illness. Influenza infection was confirmed by culture or reverse-transcriptase polymerase chain reaction. Case-control analyses were performed that used data from patients who were ill without influenza (hereafter, "test-negative control subjects") and data from asymptomatic control subjects from the population (hereafter, "traditional control subjects"). Vaccine effectiveness (VE) was estimated as [100 x (1-adjusted odds ratio)]. Influenza isolates were antigenically characterized.

RESULTS

Influenza was detected in 167 (20%) of 818 patients in 2004-2005, in 51 (14%) of 356 in 2005-2006, and in 102 (11%) of 932 in 2006-2007. Analyses that used data from test-negative control subjects showed that VE was 10% (95% confidence interval [CI], -36% to 40%) in 2004-2005, 21% (95% CI, -52% to 59%) in 2005-2006, and 52% (95% CI, 22% to 70%) in 2006-2007. Using data from traditional control subjects, VE for those seasons was estimated to be 5% (95% CI, -52% to 40%), 11% (95% CI, -96% to 59%), and 37% (95% CI, -10% to 64%), respectively; confidence intervals included 0. The percentage of viruses that were antigenically matched to vaccine strains was 5% (3 of 62) in 2004-2005, 5% (2 of 42) in 2005-2006, and 91% (85 of 93) in 2006-2007.

CONCLUSIONS

Influenza VE varied substantially across 3 seasons and was highest when antigenic match was optimal. VE estimates that used data from test-negative control subjects were consistently higher than those that used data from traditional control subjects.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Belongia EA
Epidemiology Research Center, Marshfield Clinic Research Foundation, Marshfield, Wisconsin 54449, USA. belongia.edward@marshfieldclinic.org
Kieke BA
No affiliation info available
Donahue JG
No affiliation info available
Greenlee RT
No affiliation info available
Balish A
No affiliation info available
Foust A
No affiliation info available
Lindstrom S
No affiliation info available
Shay DK
No affiliation info available
Marshfield Influenza Study Group
No affiliation info available

MeSH

AdolescentAdultAgedCase-Control StudiesChildChild, PreschoolFemaleHumansInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza A virusInfluenza B virusInfluenza VaccinesInfluenza, HumanMaleMiddle AgedPopulation SurveillanceReverse Transcriptase Polymerase Chain ReactionSeasonsTreatment OutcomeVaccines, InactivatedWisconsinYoung Adult

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

19086915